G-CSF-primed haplo-identical HSCT with intensive immunosuppressive and myelosuppressive treatments does not increase the risk of pre-engraftment bloodstream infection: a multicenter case–control study
- 78 Downloads
A multicenter retrospective study in 131 patients (44 females/87 males) with hematological disorders who underwent G-CSF-primed/haplo-identical (Haplo-ID) (n = 76) or HLA-identical (HLA-ID) HSCT (n = 55) from February 2013 to February 2016 was conducted to compare the incidence and risk factors for pre-engraftment bloodstream infection (PE-BSI). In the Haplo-ID group, 71/76 patients with high-risk (n = 28) or relapsed/refractory hematological malignancies (n = 43) received FA5-BUCY conditioning (NCT02328950). All received trimethoprim–sulfamethoxazole (TMP–SMX) prophylaxis. Blood cultures and catheter tip cultures were obtained to confirm the BSI. PE-BSI was detected in 24/131 HSCT patients (18/76 in Haplo-ID and 6/55 in HLA-ID) after 28 febrile neutropenic episodes. Among 28 isolates for the 24 patients, 21 (75%) were Gneg bacteria, 6 (21.4%) Gpos and 1 (3.6%) fungi. Bacteria sources were central venous line infection (7/29.2%), gastroenteritis (6/25%), lower respiratory tract infection (LRTI; 5/20.8%), perianal skin infection (4/16.7%), and unknown (2/8.3%). The duration of neutropenia (P = 0.046) and previous Gneg bacteremia (P = 0.037) were important risk factors by univariate analysis, while the type of HSCT was not. A trend of TMP–SMX-resistant BSI in both groups may be due to routine antibacterial prophylaxis strategies. Our data show that G-CSF-primed Haplo-ID HSCT did not increase the risk of PE-BSI, even with intensive immunosuppressive treatments.
KeywordsHaplo-identical HSCT Immunosuppressive and myelosuppressive treatments Pre-engraftment Bloodstream infection
This work was supported in part by the National and Fujian Provincial Key Clinical Specialty Discipline Construction Program, China; National High Technology Research and Development Program of China; 863 program (2012AA02A505); National Public Health Grand Research Foundation (201202017); National Natural Science Foundation of China (81570162, 81700131, 81870138); Fujian Provincial Key Laboratory Foundation of Hematology (2009J1004); and Natural Science Foundation of Fujian Province (2017Y9017, 2017Y9037, 2017Y9056, 2018Y0031). The authors would like to thank all the nurses and physicians at the center who all contributed to the management of patient care, and Dr. Martine Torres for her critical reading of the manuscript and editorial assistance.
Prof. Jianda Hu and Prof. Ting Yang designed and performed the research. Dr. Jinhua Ren and Dr. Qiaoxian Ling collected the data. Dr. Qiaoxian Ling performed the statistical analyses. Prof. Ting Yang interpreted the data and wrote the manuscript. All authors participated in the management of patient care. All authors critically reviewed and approved the manuscript.
Compliance with ethical standards
This study was conducted in accordance with the ethical standards of the local institutional review board (the Medical Ethics Committee of Fujian Medical University Union Hospital and the Helsinki Declaration). Informed consent was obtained from all patients and donors before they were included in the study.
Conflict of interest
The authors declare that they have no competing interests.
- 6.Hong J, Moon SM, Ahn HK, Sym SJ, Park YS, Park J, Cho YK, Cho EK, Shin DB, Lee JH (2013) Comparison of characteristics of bacterial bloodstream infection between adult patients with allogeneic and autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19(6):994–999CrossRefPubMedGoogle Scholar
- 8.Busca A, Cavecchia I, Locatelli F, D'Ardia S, De Rosa FG, Marmont F, Ciccone G, Baldi I, Serra R, Gaido E, Falda M (2012) Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis 14(1):40–48CrossRefPubMedGoogle Scholar
- 9.Parody R, Martino R, Rovira R et al (2006) Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 12:734–748CrossRefPubMedGoogle Scholar
- 11.Marena C, Zecca M, Carenini ML, Bruschi A, Bassi ML, Olivieri P, Azzaretti S, Locatelli F (2001) Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infect Control Hosp Epidemiol 22(8):510–517CrossRefPubMedGoogle Scholar
- 12.Junghanss C, Marr KA, Carter RA et al (2002) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8:512–520CrossRefPubMedGoogle Scholar
- 14.Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantationrecipients: a global perspective. Biol Blood Marrow Transplant 15:1143–1238CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Center for International Blood and Marrow Transplant Research (CIBMTR); National Marrow Donor Program (NMDP); European Blood and Marrow Transplant Group (EBMT); American Society of Blood and Marrow Transplantation (ASBMT); Canadian Blood and Marrow Transplant Group (CBMTG); Infectious Disease Society of America (IDSA); Society for Healthcare Epidemiology of America (SHEA); Association of Medical Microbiology and Infectious Diseases Canada (AMMI); Centers for Disease Control and Prevention (CDC) (2009) Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 44(8):453–558CrossRefGoogle Scholar
- 16.Yokoe D, Casper C, Dubberke E, Lee G, Muñoz P, Palmore T, Sepkowitz K, Young JA, Donnelly JP, Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention (2009) Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant 44(8):495–507CrossRefPubMedGoogle Scholar
- 17.Xu LP, Chen H, Chen J et al (2018) The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 11(1):33CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Network N C C. Genetic/familial high-risk assessment: breast and ovarian[J]. NCCN Clinical PracticeGoogle Scholar
- 24.Yang T, Lin Q, Ren J, Chen P, Yuan X, Luo X, Liu T, Zheng J, Zheng Z, Zheng X, Chen X, Zhang L, Zheng H, Chen Z, Hua X, Le S, Li J, Chen Z, Hu J (2016) A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies. Oncotarget 7(48):78773–78786PubMedPubMedCentralGoogle Scholar
- 25.Al-Zahrani H, Nassar A, Al-Mohareb F, Al-Sharif F, Mohamed S, Al-Anazi K, Patel M, Rasheed W, Saleh AJ, Bakr M, Ahmed S, Ibrahim K, Hussain F, Elkum N, Elhassan T, Nurgat Z, Chaudhri N, Aljurf M (2011) Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia. Biol Blood Marrow Transplant 17(5):717–722CrossRefPubMedGoogle Scholar
- 26.Kim H, Lee JH, Joo YD, Bae SH, Hyun MS, Lee JH, Kim DY, Lee WS, Ryoo HM, Kim MK, Park JH, Lee KH, Cooperative Study Group A for Hematology (COSAH) (2012) A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Ann Hematol 91(9):1459–1469CrossRefPubMedGoogle Scholar
- 27.Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, Holler E, Finke JM (2008) Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 112(2):415–425CrossRefPubMedGoogle Scholar
- 31.Horan T, Gaynes R (2004) Surveillance of nosocomial infections. In: Hospital epidemiology and infection control, 3rd edn. Philadelphia, Lippincott, Williams & Wilkeins, pp 1659–1702Google Scholar
- 33.Chinese Society of Hematology, Chinese Medical Association (2012) Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever. Zhonghua Xue Ye Xue Za Zhi 33(8):693–696Google Scholar
- 34.Chinese Society of Hematology, Chinese Medical Association; Chinese Medical Doctor Association, Hematology Branch (2016) Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2016). Zhonghua Xue Ye Xue Za Zhi 37(5):353–359Google Scholar
- 35.Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M, ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica 98(12):1826–1835CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M, ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN (2013) Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica 98(12):1836–1847CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Tang W, Fan X, Wang L, Hu J (2015) Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study. Medicine 94(15):e706CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Johansson JE, Brune M, Ekman T. (2001) The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning[J]. Bone marrow transplantation 28(8):737Google Scholar
- 43.Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D et al (2009) Bloodstream infections in allo-geneic hematopoietic stem cell transplant recipients: re-emergence of gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 15:47–53CrossRefPubMedGoogle Scholar
- 44.Therriault BL, Wilson JW, Barreto JN, Estes LL (2010) Characterization of bacterial infection in allogenic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxacycline. Mayo Clin Proc 85(8):711–816CrossRefPubMedPubMedCentralGoogle Scholar